Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis Andrew BurkeDaniel SmithJason A. Roberts Review Article 13 May 2021 Pages: 1081 - 1102
Clinical Pharmacokinetics of Triazoles in Pediatric Patients Didi BuryWim J. E. TissingRoger J. Brüggemann Review Article Open access 18 May 2021 Pages: 1103 - 1147
Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review Luka VerrestErica A. WilthagenThomas P. C. Dorlo Systematic Review Open access 01 June 2021 Pages: 1149 - 1169
Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects Andreas B. JordyMuna AlbayatyTine A. Bækdal Original Research Article Open access 30 March 2021 Pages: 1171 - 1185
Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug–Drug Interactions Marie-Emilie WilleminThomas K. Van Der MadeJan Snoeys Original Research Article 10 April 2021 Pages: 1187 - 1199
Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting Tom C. ZwartAiko P. J. de VriesDirk Jan A. R. Moes Original Research Article Open access 17 April 2021 Pages: 1201 - 1215
Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and Adults Theodoros PapathanasiouHenrik AgersøRasmus Juul Kildemoes Original Research Article Open access 17 April 2021 Pages: 1217 - 1226
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis Per Olsson GisleskogBelén ValenzuelaItalo Poggesi Original Research Article 29 April 2021 Pages: 1227 - 1237
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis Belén ValenzuelaJuan-José Pérez-RuixoItalo Poggesi Original Research Article 29 April 2021 Pages: 1239 - 1250
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor Angela Joubert JamesCatherine C. SmithErkut Bahceci Correction Open access 23 July 2021 Pages: 1251 - 1251